3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Solid Tumor
1
Interventions
Injections
6
pembrolizumab
5
senaparib
4
toripalimab
3
tislelizumab
3
Bevacizumab
3
sintilimab
2
Technetium
2
Specimen Handling
2
Nivolumab
2
Ipilimumab
2
Fluorodeoxyglucose F18
2
Carboplatin
2
Blood Specimen Collection
2
zimberelimab
1
tumor-cells apoptosis factor, human
1
tazemetostat
1
spartalizumab
1
sacituzumab govitecan
1
rucaparib
1
osimertinib
1
olaparib
1
etoposide phosphate
1
enzalutamide
1
envafolimab
1
cemiplimab
1
cedazuridine
1
atezolizumab
1
WW Domain-Containing Oxidoreductase
1
Ultrasonography, Doppler
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Solid Tumor
×
Off-Label Use
×
1 year
×
Clear all
NCT06956248
2026-05-13
IMPACT-INSPIRE
National Cancer Centre, Singapore
Recruiting
50 enrolled